Findings from the CONCEPTT trial, which analysed 220 pregnant women with type 1 diabetes, reveal that the glucose management indicator (GMI)—commonly used as a substitute for HbA1c—shows limited validity during pregnancy, underscoring the need for cautious interpretation in this setting. Across 12, 24, and 34 weeks’ gestation, GMI demonstrated higher bias—particularly in the first and third trimesters—and provided no added predictive value for maternal or neonatal outcomes compared with HbA1c, mean CGM glucose, or time-in-range metrics. These results underline the need for caution when using GMI in pregnancy and emphasize the importance of relying on validated glucose markers to guide clinical decision-making. To read more, click here Is GMI reliable for managing pregnant women with T1D in your practice?
##Reference## Claire L. Meek, Denice S. Feig, Eleanor M. Scott, Rosa Corcoy, Helen…
